Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | Chief Commercial Officer | February 05, 2026 | February 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date February 05, 2026 · Filed February 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.43 · Expires 2036-02-05 | Direct | 38,517 |
Reported balance
After 2026-02-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-05 · Grant · Acquired 38,517 · Balance 38,517 F1: The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 05, 2026 Filed Feb 9, 2026 16:08 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (Right to Buy) · Derivative | 38,517 | $0.00 Strike: $76.43 | $0.00 |
DisclosureSEC source: 0001104659-26-012067 · tm265512-4_4seq1.xml · derivative · entry 1 Kline Ashley Hartmann · CIK 0002071433 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,517 Underlying: Common Stock · 38,517 shares Expires 2036-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| May 27, 2025 Filed Jun 3, 2025 21:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 111,496 | $0.00 Strike: $22.94 | $0.00 |
DisclosureSEC source: 0001583648-25-000030 · edgardoc.xml · derivative · entry 2 Kline Ashley Hartmann · CIK 0002071433 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,496 Underlying: Common Stock · 111,496 shares Expires 2035-05-26 F1 · derivative.exercise_date: The option vests 25% on May 27, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
| May 27, 2025 Filed Jun 3, 2025 21:15 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantIncentive Stock Option (right to buy) · Derivative | 17,436 | $0.00 Strike: $22.94 | $0.00 |
DisclosureSEC source: 0001583648-25-000030 · edgardoc.xml · derivative · entry 1 Kline Ashley Hartmann · CIK 0002071433 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,436 Underlying: Common Stock · 17,436 shares Expires 2035-05-26 F1 · derivative.exercise_date: The option vests 25% on May 27, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.